USDA withdraws plan to limit salmonella levels in raw poultry
The Agriculture Department will not require poultry companies to limit salmonella bacteria in their products, halting a Biden Administration effort to prevent food poisoning from contaminated meat.
The department on Thursday said it was withdrawing a rule proposed in August after three years of development. Officials with the USDA's Food Safety and Inspection Service cited feedback from more than 7,000 public comments and said they would 'evaluate whether it should update' current salmonella regulations.
The rule would have required poultry companies to keep levels of salmonella bacteria under a certain threshold and test for the presence of six strains most associated with illness, including three found in turkey and three in chicken. If the levels exceeded the standard or any of those strains were found, the poultry couldn't be sold and would be subject to recall, the proposal had said.
Advertisement
3 After three years of development, the Agriculture Department said it was withdrawing a rule proposed in August on limiting salmonella bacteria.
manjurul – stock.adobe.com
The plan aimed to reduce an estimated 125,000 salmonella infections from chicken and 43,000 from turkey each year, according to USDA. Overall, salmonella causes 1.35 million infections a year, most through food, and about 420 deaths, according to the U.S. Centers for Disease Control and Prevention.
The withdrawal drew praise from the National Chicken Council, an industry trade group, which said the proposed rule was legally unsound, misinterpreted science, would have increased costs and create more food waste, all 'with no meaningful impact on public health.'
'We remain committed to further reducing salmonella and fully support food safety regulations and policies that are based on sound science,' said Ashley Peterson, the group's senior vice president of science and regulatory affairs.
Advertisement
3 The rule would have required poultry companies to keep levels of salmonella bacteria under a certain threshold and test for the presence of six strains most associated with illness, with some found in chicken and turkey.
didesign – stock.adobe.com
But the move drew swift criticism from food safety advocates, including Sandra Eskin, a former USDA official who helped draft the plan.
The withdrawal 'sends the clear message that the Make America Healthy Again initiative does not care about the thousands of people who get sick from preventable foodborne salmonella infections linked to poultry,' Eskin said in a statement.
Advertisement
The proposed rule had been regarded as a food safety victory similar to a 1994 decision to ban certain strains of dangerous E. coli bacteria from ground beef after deadly outbreaks, said Sarah Sorscher, of the Center for Science in the Public Interest.
3 'Make no mistake: Shipping more salmonella to restaurants and grocery stores is certain to make Americans sicker,' Sarah Sorscher, of the Center for Science in the Public Interest, said.
AP
'Make no mistake: Shipping more salmonella to restaurants and grocery stores is certain to make Americans sicker,' Sorscher said.
Advertisement
Earlier this month, the USDA said it would delay by six months the enforcement of a final rule regulating salmonella levels in certain breaded and stuffed raw chicken products. Enforcement, which was set for May 1, now begins Nov. 3.
That covers foods such as frozen chicken cordon bleu and chicken Kiev dishes that appear to be fully cooked but are only heat-treated to set the batter or coating. Such products have been linked to at least 14 salmonella outbreaks and at least 200 illnesses since 1998, according to the CDC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Healthcare companies chase cures and capital in South Florida
Leaders of hundreds of public healthcare companies are in South Florida this week, talking up their innovations and financial performances to attract and impress investors at the Goldman Sachs Global Healthcare Conference. Consumers will find that nearly every disease or ailment they suffer from has a treatment in development, as big and small companies see opportunities in Americans' desire to live longer and pain-free. From new devices for sleep apnea to drugs for cancer, to creams for chronic itching and drops for improved eyesight, advances are underway that hold promise. Presenters like LENZ Therapeutics wowed the audience on Monday with product updates, such as an eyedrop that lasts all day and allows for close-up vision, which most people use reader glasses to achieve. The eye drops target a market of over 128 million people in the U.S. who need help with near vision. This year, new factors are affecting how quickly consumers can obtain a drug or device to improve or save their lives, according to company executives. The uncertainty in Washington, D.C., looms large. Policy turbulence, regulatory uncertainty, shakeups at health agencies and President Donald Trump's aggressive stance on drug pricing and tariffs factor into the future for the devices and treatments working their way toward the marketplace. Anti-Trump protests will unfold across South Florida this weekend. Here's what to expect Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives Hidden charges? Patients often face massive bills when Florida hospitals don't provide costs upfront Native Americans hurt by federal health cuts, despite RFK Jr.'s promises of protection Georgia's experience raises red flags for Medicaid work requirement moving through Congress 'This year, the biggest questions we are opening with for all of our companies is the policy calculus in Washington, D.C., and how that could play out across the healthcare sector,' said Asad Haider, Goldman Sachs' head of the healthcare business unit within Global Investment Research and the lead analyst for the U.S. pharmaceuticals sector. 'The starting point in all these presentations is give us the landscape on where things could go with respect to what's going on in Washington, D.C.' Over 200 top managerial teams attended the conference, representing every corner of the healthcare field, from major pharmaceutical companies to small biotech firms. The goal of the three-day conference was to provide institutional investors with insights into companies' business plans, data, and progress, particularly at a strategic mid-year point. Innovation hotspots this year include treatments for weight loss, with a focus on oral drugs replacing injectables and medications to help maintain a healthy weight. Another is oncology, immunology, and neuroscience with breakthroughs to detect diseases earlier and find new drug delivery methods. Several companies at the conference have formed partnerships with companies across the globe to access new markets, technologies, and expertise. China is emerging as a global leader in biotechnology, with numerous U.S. and European companies collaborating with or licensing technologies from Chinese companies. Summit Therapeutics, a Miami-based company, drew interest at the conference with its innovative cancer-fighting, bispecific antibody, ivonescimab, and its partnership with a Chinese laboratory. Ivonescimab has shown promise in previous trials in China and additional trials are underway combining the drug with chemotherapy to target non-small-cell lung cancer. 'We have over 22 or 23 different trials going on or completed or going to start,' said Maky Zangaheh, co-CEO of Summit Therapeutics. 'One element of that is a phase 3 trial that China and us are combining with over 3,000 patients enrolled, so we will have a good safety profile and efficacy profile in many different therapeutic areas. From a commercialization point of view, we are already in China and have two Chinese approvals, which is significant progress.' Doron Junger, of Sanvia Capital, a South Florida biotech investment firm, said he attended the conference looking to invest in companies developing innovations that could address large or niche markets in a more meaningful way. A few have caught his attention; however, he is cautious about those who tout therapies in their pipelines. 'More drug trials fail than succeed, and while there is a lot of innovation in this industry in areas of need like oncology and chronic diseases, even at a late stage, there is potential for a clinical trial to fail to show an advantage over a placebo group,' he said. 'Even if it does, that trial has to pass muster with the rigorous standards the FDA sets for approval.' On Monday, Arcturus Therapeutics of San Diego presented an update on a daily inhaled treatment for Cystic Fibrosis, which could be a breakthrough for the disease. Additionally, BioAge Labs CEO Kristen Fortney explained how her California company uses samples from a repository to study the biology of human aging and develop new therapies for obesity. Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space and believes it can improve upon oral therapies now on the market, she said. 'More and more people are aging, and by definition, they are using more healthcare,' said Haider of Goldman Sachs. 'The aging population is going to need new drugs, better drugs, faster drugs for diabetes and cardiometabolics and oncology and all of these diseases that potentially could kill you. There will be innovation, but what are we willing to pay for that innovation?' Will regulations make it more difficult and/or costly for people to access the devices and drugs that can save their lives? Haider said drug pricing will be a key concern for both consumers and investors. 'Everyone is chasing big caps, big targets, but there will be winners and losers.' South Florida Sun Sentinel health reporter Cindy Goodman can be reached at cgoodman@
Yahoo
21 minutes ago
- Yahoo
One year without RECA: Justice delayed for radiation victims in Idaho and beyond
Craters across the Frenchman Flats in Nevada dot the landscape where the U.S. government tested hundreds of nuclear weapons. Under a proposed expansion of the Radiation Compensation Exposure Act, anyone in states like Utah or Idaho diagnosed with certain cancers caused by nuclear testing would have been eligible for compensation. But the expansion was cut from Congress' defense spending bill, and the protections in the act were allowed to expire. () June 10 marks one year since the U.S. Congress allowed the Radiation Exposure Compensation Act, or RECA, to expire — abandoning thousands of Americans who sacrificed their health in the name of national security. RECA provided critical compensation for medical expenses to uranium miners, mill workers, and 'downwinders' exposed to radiation during Cold War-era nuclear testing and weapons development. But even when it was active, RECA was incomplete, excluding entire communities — including Idahoans — who suffered the same devastating consequences. From 1945 to 1992, the U.S. government detonated over a thousand nuclear weapons, scattering radioactive fallout across the West. America's nuclear 'downwinders' deserve justice While RECA compensated some downwinders in Nevada, Utah, and Arizona, Idahoans — who endured the same invisible poison — were left out. Uranium miners employed after 1971 and St. Louis communities used as dumping grounds for Manhattan Project Waste were also excluded from RECA compensation. The consequences have been deadly. Research shows that radiation exposure leads to cancers, heart disease, genetic mutations, and immune disorders —with women and children at greatest risk. Yet for decades, the government dismissed these victims as collateral damage, treating rural Westerners and Indigenous communities as expendable. Atomic Energy Commission documents revealed the attitude of the officials making decisions, that we were just a bunch of cowboys, Indians, and Mormons, and a 'low-use segment' of the population. Western states were deemed 'low-population,' as if rural lives mattered less. The Marshall Islands, subjected to 67 nuclear tests, were treated as a sacrifice zone, and officials justified this; they are 'more like us than the mice' is the quote from an Atomic Energy Commission official in 1956. Dismissing Nevada Test Site downwinders and other nuclear weapons test victims as insignificant reflects a brutal truth: the U.S. government calculated whose life had worth and whose did not. But cancer doesn't discriminate. Families in Idaho, Montana, Wyoming, New Mexico, and beyond have watched generations suffer from rare leukemias, thyroid diseases, brain cancers, and clusters of tumors. Many never knew their illnesses were tied to nuclear testing — until it was too late. RECA should be reinstated and expanded to cover all radiation victims, including people like: Idaho downwinders Post-1971 uranium workers Other communities excluded from fallout zones Congress has a choice: pass RECA in the next must-pass Big, Beautiful, Bill, or continue to let victims die waiting. This isn't just about compensation — it's about admitting the full cost of America's nuclear legacy and justice for victims. Our representatives in Congress will make better decisions if they hear from residents about how expansion of RECA would affect them. Research your family history — were there unexplained cancers, thyroid conditions, or stillbirths? Radiation's effects linger for generations. Speak up — this isn't ancient history. Every day RECA lapses, more people suffer. We can't allow our government to wait for people to die. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Associated Press
32 minutes ago
- Associated Press
Statement from the American Nurses Association on the Department of Health and Human Services' Restructuring of the Advisory Committee for Immunization Practices
ANA Urges Inclusion of Nurses and Healthcare Experts on ACIP to Restore Public Trust in Vaccines and Reinforce Evidence-Based Policy SILVER SPRING, Md., June 11, 2025 /PRNewswire/ -- The American Nurses Association (ANA) is concerned by the Department of Health and Human Services' (HHS) recent action to restructure the Advisory Committee for Immunization Practices (ACIP). While the intent may be to restore integrity and public trust in vaccine science, this sweeping action risks achieving the opposite. ANA acknowledges that the previous Administration took unprecedented action that prevented this Administration from selecting ACIP representatives through the normal application and nomination process. While we understand the impetus to establish leadership in the process, we are concerned that the complete removal of all ACIP members could further erode public confidence in both the process and vaccines themselves. Restoring trust in vaccines is critical to safeguard public health, ensuring all children reach adulthood, and enabling all Americans to live healthy, productive lives. Vaccines are foundational to public health. They protect individuals, families, and communities from preventable disease, and they remain a cornerstone of our national and global response to emerging health threats. The public must trust not only the science behind vaccines, but the processes by which decisions are made about their use. That trust is built through transparency, consistency, and representation of frontline perspectives. ANA urges HHS to ensure the nursing perspective is meaningfully represented as new ACIP members are selected. Nurses play a vital role in immunization efforts: they educate patients, advocate for accessible vaccination practices, and uphold immunization recommendations. Nurses are often the first line of defense against vaccine-preventable diseases and bring essential, evidence-based insight to any conversation on public health. As the most trusted profession in the United States, nurses understand their ethical obligation to advance evidence-based approaches and to provide the best available information for patients and the public. Their expertise, clinical experience, and leadership in both community and acute care settings make them indispensable voices in national vaccine policy discussions. ANA stands ready to support HHS in identifying qualified nurses to serve on ACIP and contribute to restoring public trust in immunization practices. ANA remains committed to engaging in this important dialogue and supporting efforts that center public health, science, and evidence-based practice. We look forward to continuing collaboration with HHS to ensure nurses—and the patients they serve—are represented in critical public health decisions. About the American Nurses Association As the oldest organization representing more than 5 million registered nurses, the American Nurses Association stands at the forefront of advancing nursing excellence. The association harnesses The Power of Nurses™ to champion the profession and drive transformation in healthcare. Through legislative and political advocacy, comprehensive educational services, and the profession's leading Code of Ethics and Scope and Standards, the association empowers nurses across every specialty and practice setting. The association is committed to ensuring healthy work environments, shaping pioneering policies, and cultivating partnerships that enhance both the nursing profession and the broader healthcare experience. MEDIA CONTACT: [email protected] View original content to download multimedia: SOURCE American Nurses Enterprise
